Ballentine Partners, LLC Replimune Group, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 21,944 shares of REPL stock, worth $197,276. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,944Holding current value
$197,276% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding REPL
# of Institutions
194Shares Held
80.4MCall Options Held
8.69MPut Options Held
2.28M-
Baker Bros. Advisors LP New York, NY11MShares$99.3 Million0.38% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.31MShares$74.7 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.4MShares$57.5 Million0.36% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$42.4 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.16MShares$37.4 Million3.48% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $443M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...